Navigation Links
Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling
Date:4/14/2008

Data presented at AACR 2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study demonstrating that the Company's experimental drug candidate, brostallicin, killed colon and ovarian cancer cells regardless of their p53 status. The study, conducted by Cristina Geroni, Ph.D., et al of Nerviano Medical Sciences in Milan, Italy suggests that while brostallicin is more effective in cells with normal p53 status, cells with abnormal or missing p53 are also killed when treated. P53 is a protein that regulates the cell cycle and acts as a tumor suppressor. Patient tumors that have low or absent p53 are less responsive to standard therapy and have a worse prognosis.

"The results of this study support the further clinical development of brostallicin. They also provide deeper insight into brostallicin's context of vulnerability concerning different types of p53 protein, and where it is most effective. In our continued efforts to make cancer more treatable, results like these increase our understanding of cancer and potential therapies, and bring us closer to being able to offer the right drugs to the right patients," said Jeffrey Jacob, CEO of SM.

This study examined brostallicin's effect on cell viability, cell cycle modulation, and the initiation of cell death in cancer cell models with either normal (also referred to as wild-type) or abnormal (mutated or absent) p53 tumor suppressor. These results were supported through tests in animal models, where brostallicin demonstrated a statistically significant effect on suppressing tumor growth. To review the poster and see more detailed information about the study, please go to http://www.celltherapeutics.com/investors_news-updates.htm.

About Brostall
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  There is still ... organization,s success. The 10th Annual Institute for Supply ... for Excellence in Supply Management is open for ... the understanding and importance of supply management by ... and best supply management practices.  Entries are due ...
(Date:7/30/2014)... Mich. , July 30, 2014 Advanced Photonix ... quarter (ending June 27, 2014) financial results on Monday, August ... be released after the close of the market and the ... the results at 4:30 p.m. EDT on the same day. ... Kurtz (CEO and Director), Rob Risser (COO ...
(Date:7/30/2014)... Inc. (NASDAQ: HOLX ) today announced its ... 2014. Third Quarter Financial Highlights and Recent ... reflecting operational growth of 0.5% and a positive currency ... the prior year. , Revenues grew in three ... grew 3.5%. , GYN Surgical revenues grew 3.5%. ...
Breaking Medicine Technology:Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17
... findings presented today show that CONCERTA® (OROS® methylphenidate ... medication with data that demonstrate a significant treatment ... 12.5 hours in children with Attention Deficit Hyperactivity ... medical condition characterized by inattention, hyperactivity and impulsivity(1) ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced unaudited financial results for the three months ended ... September 30, 2009 , As of September 30, ... equivalents and an additional $50.9 million in investment securities, ...
Cached Medicine Technology:CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 2CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 3CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 4CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 5CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 6CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/30/2014)... 30, 2014 Nationally recognized leader in ... who since September 2013 has served as president of ... new dean of the College of Nursing at University ... her leadership of the NLN, as the nation's premier ... academic nursing and research institutions in the country. ...
(Date:7/30/2014)... Daily Gossip mentions that the "Panic Away" ... way to stop anxiety and eliminate all associated symptoms. It ... less than 150,000 people in getting their lives back. , ... anxiety treatment system that will teach sufferers different techniques on ... very simple to access, as it is available in a ...
(Date:7/30/2014)... Within weeks freshman will begin to pour onto ... this will be a time of growth and the start to ... it may not be as easy as it looks. Some ... their major at least once and many will switch two or ... costs are exacerbated when switching in the later years of college. ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... July 30, 2014 Throughout the month ... with free oral cancer screenings. Using a new technological ... to detect the disease in its early stages. , ... cheek, mouth, sinuses, throat and other areas in and ... Surveillance, Epidemiology, and Ends Results (SEER) program, 30 percent ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2
... , , PASADENA, ... AIMM) today announced its licensee, BioMS Medical Corp., and ... meet the primary endpoint of delaying disease progression, as ... the two-year Phase III trial in patients with secondary ...
... EATONTOWN, N.J., July 30 Osteotech, Inc. (Nasdaq: ... for regenerative healing, announced today that its management team is scheduled ... Healthcare Conference at the Millennium Broadway Hotel in New York on ... A live, listen-only webcast of the presentation can be ...
... , , , , ... Corp. (Nasdaq: WBMD ) today announced financial results for the three ... to deliver strong results again this quarter. WebMD,s advertising revenue grew by 18% ... companies in the health and wellness markets," said Wayne Gattinella, President and CEO. ...
... , WASHINGTON, July 30 An estimated 700,100 residents ... a House health reform bill, according to state-specific analysis ... released this week by The Heritage Foundation . ... Lewin Group , a highly respected health care policy and ...
... NOVATO, Calif., July 30, BioMarin Pharmaceutical Inc. (Nasdaq: ... has issued patents covering stable tablet formulation and the approved once ... phenylketonuria (PKU). The patent for stable tablet formulation expires in ... in 2024. , , "We believe the issuance ...
... researchers say , THURSDAY, July 30 (HealthDay News) -- ... vaccine activates the immune system against the virus appear ... study finds. , According to Dutch researchers led by ... immune system goes on alert against the seasonal flu ...
Cached Medicine News:Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:WebMD Announces Second Quarter Financial Results 2Health News:WebMD Announces Second Quarter Financial Results 3Health News:WebMD Announces Second Quarter Financial Results 4Health News:WebMD Announces Second Quarter Financial Results 5Health News:WebMD Announces Second Quarter Financial Results 6Health News:WebMD Announces Second Quarter Financial Results 7Health News:WebMD Announces Second Quarter Financial Results 8Health News:WebMD Announces Second Quarter Financial Results 9Health News:WebMD Announces Second Quarter Financial Results 10Health News:WebMD Announces Second Quarter Financial Results 11Health News:WebMD Announces Second Quarter Financial Results 12Health News:WebMD Announces Second Quarter Financial Results 13Health News:WebMD Announces Second Quarter Financial Results 14Health News:WebMD Announces Second Quarter Financial Results 15Health News:WebMD Announces Second Quarter Financial Results 16Health News:WebMD Announces Second Quarter Financial Results 17Health News:WebMD Announces Second Quarter Financial Results 18Health News:WebMD Announces Second Quarter Financial Results 19Health News:Thousands of Nebraskans Could Lose Private Insurance, Study Shows 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 3Health News:Flu Shot May Be Less Effective in Those With Lupus 2
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Medicine Products: